#USA #Halifax #hemostasis #Precision BioLogic #George King Bio-Medical

Precision BioLogic Expands Its Reach Through Strategic Acquisition

Precision BioLogic Inc., a leading innovator in hemostasis diagnostics, has made significant headlines by acquiring George King Bio-Medical, Inc., a revered provider within the same domain. This strategic acquisition was officially announced on October 16, 2025, marking a pivotal moment for both organizations as they aim to enhance their market presence and drive advancements in the field of diagnostic products.

A Legacy of Care

Founded over 50 years ago, George King Bio-Medical has carved a niche in providing essential products that aid individuals suffering from bleeding disorders. Paul Empey, the CEO of Precision BioLogic, expressed enthusiasm about this acquisition: "From its inception, George King Bio-Medical has stayed true to its mission of assisting individuals affected by bleeding disorders. Both of our organizations share a common goal, and together, we will nurture existing partnerships while exploring new prospects to assist those in need in the bleeding disorders community."

Similarly, Kathryn Blasco, the CEO and President of George King Bio-Medical, emphasized the importance of continuing her father's legacy. "Joining forces with Precision BioLogic allows us to maintain our commitment to compassion and innovation. The future looks bright for both of our organizations and our customers."

Future Collaborations and Strategic Goals

The acquisition signifies more than just a merger of companies. It sets the stage for a shared vision aimed at enhancing customer relations and operational efficiencies under the Precision BioLogic umbrella. Both organizations will continue to focus on their current operations while setting up long-term strategic plans to innovate and expand their product ranges.

About George King Bio-Medical
Founded in 1973 by George J. King, the company has remained committed to addressing the needs of the community affected by bleeding disorders. They provide high-quality fresh frozen human plasma for clinical laboratories, powered by a stringent quality program and an expanding plasma donation initiative. Currently based in Overland Park, Kansas, their dedication to quality and customer service has made them a trusted provider in the industry.

About Precision BioLogic
Precision BioLogic specializes in the development, manufacturing, and marketing of CRYOcheck™, a product line utilized by healthcare professionals globally to diagnose coagulation disorders. The company has broadened its clinical and research offerings since acquiring Affinity Biologicals in November 2018, which included a diverse range of coagulation-related antibodies and other complementary services.

As both companies integrate their operations, patients and healthcare providers can expect enhanced product offerings that reflect their shared dedication to exceptional quality and support in hemostasis diagnostics. This acquisition illustrates the proactive stance Precision BioLogic is taking to strengthen its influence in the industry and improve health outcomes for patients suffering from bleeding disorders.

Contact Information

For further inquiries about this acquisition or for more information about either organization, please reach out to Elaine Benoit, Marketing Communications Lead at Precision BioLogic, via email at [email protected] or by phone at 902-430-7795.

In conclusion, the merging of Precision BioLogic and George King Bio-Medical not only aligns with their mutual commitments to innovation and quality but also signals a brighter future for professionals and patients alike in the field of hemostasis diagnostics.